Key terms

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

VIRX Financials

1-year income & revenue

Key terms

VIRX Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

VIRX Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms